Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.59 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073124 | 0.93 | HPGDS (0.51) | HPGDSUSP30PDE10AGABRA5MAP4K4 | |
| SCHEMBL2071296 | 0.90 | HPGDS (0.57) | HPGDSUSP30PDE10AGABRA5ADORA3 | |
| SCHEMBL2071279 | 0.90 | HPGDS (0.61) | HPGDSUSP30GABRA5MAP4K4ADORA3 | |
| SCHEMBL2073405 | 0.89 | HPGDS (0.62) | HPGDSUSP30GABRA5ADORA3RET | |
| SCHEMBL2073348 | 0.89 | HPGDS (0.60) | HPGDSUSP30PDE10AGABRA5MAP4K4 | |
| SCHEMBL2073833 | 0.88 | HPGDS (0.55) | HPGDSUSP30PDE10AGABRA5MAP4K4 | |
| SCHEMBL2073092 | 0.88 | HPGDS (0.58) | HPGDSUSP30PDE10AGABRA5MAP4K4 | |
| SCHEMBL2072753 | 0.87 | HPGDS (0.64) | HPGDSUSP30PDE10AGABRA5MAP4K4 | |
| SCHEMBL13572979 | 0.86 | HPGDS (0.45) | HPGDSUSP30PDE10AGABRA5MAP4K4 | |
| SCHEMBL16496810 | 0.86 | HPGDS (0.45) | HPGDSUSP30PDE10AGABRA5MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2129660-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | Pfizer Products Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HPGDS 984/4885USP30 4416/4885PDE10A 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.